Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Sees Sharp Rise In Clinical Trial Applications Via New Portal

Executive Summary

Notably more clinical trial applications were submitted to the new Clinical Trial Information System in July compared with previous months, according to new data that also shed light on how many submissions have been approved or rejected.

You may also be interested in...

So Far So Good: EU Member States On ‘Limited’ Experience With Clinical Trial Portal

At a recent webinar on the EU Clinical Trial Information System (CTIS), representatives from different EU member states said the new system was working well and highlighted certain “good practices” for study sponsors to consider. 

First Clinical Trial Approved Through New EU Portal

The EU’s new trial portal and database system, which allows the submission of a single application to conduct a study across any number of EU countries, has yielded its first fruit in the form of an approval for a non-commercial Swedish clinical trial involving cardiac arrest patients.

NZ Govt Moves To Speed Drug Access Amid Plans To Wipe Out Major New Act

A parallel assessment mechanism that will allow new medicines in any therapeutic area to be considered for funding sooner is being introduced in New Zealand, where the new coalition government is working to repeal last year’s landmark Therapeutic Products Act.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts